Sage Therapeutics, a clinical-stage biopharmaceutical company developing medicines to treat life-altering central nervous system (CNS) disorders, announced that the FDA Psychopharmacologic Drugs Advisory Committee (PDAC) and Drug Safety and Risk Management Advisory Committee (DSaRM) jointly voted (17 yes, 1 no) that data support the favorable benefit-risk profile of Zulresso (brexanolone) injection for the treatment of postpartum…